Twice-yearly depemokimab demonstrates early and sustained improvements in peak expiratory flow and daily asthma symptoms in patients with uncontrolled asthma over 52 weeks in SWIFT-1/-2
作者
ARNAUD AB BOURDIN,Rohit K. Katial,Sameer K. Mathur,Nicholas Bird,Loretta Jacques,Claire E. Tacon,Andrew M. Platt,Ian Douglas Pavord
出处
期刊:The European respiratory journal [European Respiratory Society] 日期:2026-09-05卷期号:: PA2561-PA2561